Melanoma of the skin

Race/ethnicity rates per 100k (SEER Stat Facts)

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

USPSTF 2023 I · Asymptomatic adults · Visual exam — insufficient evidence

Encoded on the published track as an eligibility table — not a personal recommendation. USPSTF-skin-2023

ACS early-detection pointer

ACS 2026 · People without basal-cell symptoms · ACS BCC type page (2026): ACS does not have guidelines for the early detection of skin cancer. Many doctors recommend checking your own skin regularly; that monthly self-exam is named, not encoded. Complementary to the encoded USPSTF 2023 I visual-exam statement and the 2018 UV-counseling pointer. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.

Cited ACS statement only. Not a screening engine. ACS-bcc-detect

ACS early-detection pointer

ACS 2026 · People without melanoma symptoms · ACS melanoma type page (2026): ACS does not have guidelines for the early detection of skin cancer. Monthly self-exam, dermoscopy, and mole mapping are named, not encoded. Complementary to the BCC type-page note, the encoded USPSTF 2023 I visual-exam statement, and the 2018 UV-counseling pointer. Melanoma and keratinocyte carcinoma stay labeled separately. Not a population visual-screen engine.

Cited ACS statement only. Not a screening engine. ACS-melanoma-detect

ACS early-detection pointer

ACS 2025 · People without Merkel-cell symptoms · ACS Merkel type page (2025): ACS does not have guidelines for the early detection of skin cancer. A monthly self-exam is named, not encoded. Complementary to the BCC and melanoma type-page notes, the encoded USPSTF 2023 I visual-exam statement, and the 2018 UV-counseling pointer. Merkel cell carcinoma stays labeled separately from melanoma and keratinocyte carcinoma. Not a population visual-screen engine.

Cited ACS statement only. Not a screening engine. ACS-merkel-detect

ACS early-detection pointer

ACS 2025 · People without Kaposi sarcoma symptoms who are not at increased risk · ACS Kaposi type page (2025): there are no recommended routine screening tests to look for Kaposi sarcoma in people who are not at increased risk. Regular exams for people with HIV are named, not encoded. Complementary to the BCC, melanoma, and Merkel type-page notes. Kaposi sarcoma stays labeled separately. Not a population visual-screen or HIV-KS screening engine.

Cited ACS statement only. Not a screening engine. ACS-kaposi-detect

USPSTF counseling pointer

USPSTF 2018 B/C/I · Asymptomatic people without a history of skin cancer · USPSTF 2018 Skin Cancer Prevention: Behavioral Counseling — Grade B: counsel persons aged 6 months to 24 years with fair skin types about minimizing UV exposure. Grade C: selectively offer counseling to adults older than 24 with fair skin types. Grade I: insufficient evidence for counseling adults about skin self-examination. This demo encodes the 2023 visual-exam I statement, not this counseling rec. Not equivalent. Not a population visual-screen program.

Cited counseling statement only. Do not claim equivalence to the visual-exam I statement. USPSTF-skin-counsel-2018

Surveillance pointer

AAD-skin cited · encoded flag · AAD-class specialist follow-up after melanoma. No invented NCCN month table.

Named public source only. Not a personal follow-up calendar. AAD-skin

Surveillance pointer

ACS-melanoma-follow 2026 · cited only · ACS after-treatment page names close follow-up after melanoma because of recurrence and a higher chance of a new melanoma or other skin cancer. Cadence depends on stage. Those months are not encoded. Complementary to the AAD specialist-calendar flag. No invented NCCN month table.

Named public source only. Not a personal follow-up calendar. ACS-melanoma-follow

Surveillance pointer

ACS-bcc-follow 2026 · cited only · ACS after-treatment page names typical follow-up visits about every 6 to 12 months after basal cell carcinoma, plus a monthly self-exam. Those months are not encoded. Complementary to the AAD melanoma flag and the melanoma ACS row. Keratinocyte carcinoma stays labeled separately. No invented NCCN month table.

Named public source only. Not a personal follow-up calendar. ACS-bcc-follow

Surveillance pointer

ACS-merkel-follow 2025 · cited only · ACS living-as-a-survivor page names typical Merkel follow-up exams every 3 to 6 months for the first few years, then every 6 to 12 months, plus optional PET/CT for higher-risk disease. Those months are not encoded. Complementary to the AAD melanoma flag and the melanoma / BCC ACS rows. Merkel cell carcinoma stays labeled separately. No invented NCCN month table.

Named public source only. Not a personal follow-up calendar. ACS-merkel-follow

Surveillance pointer

ACS-kaposi-follow 2025 · cited only · ACS after-treatment page names close follow-up during and between Kaposi sarcoma treatments, with exams and possible blood or imaging tests. Those months are not encoded. Complementary to the AAD melanoma flag and the other ACS skin follow rows. Kaposi sarcoma stays labeled separately. Not an HIV-KS calendar engine.

Named public source only. Not a personal follow-up calendar. ACS-kaposi-follow

Surveillance pointer

ACS-melanoma-follow 2026 · cited only · ACS after-treatment page says most experts do not recommend any other specific tests to look for second cancers unless you have symptoms. ACS colorectal and lung guidelines are named, not encoded as extra melanoma screens. Complementary to the AAD specialist-calendar flag and the other ACS skin follow rows. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-melanoma-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names a cancer treatment summary and survivorship care plan, plus cancer-related fatigue that can last months or years. Those names are not encoded. Complementary to the AAD melanoma flag and the other ACS skin follow rows. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the skin printout and the AAD first row. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

AAD-skin cited · cited only · In-field skin awareness after chest radiation is a Hodgkin late-effect flag, not a melanoma incidence engine.

Named public source only. Flags are not dose reconstruction. AAD-skin

Toxicity pointer

ACS-melanoma-follow 2026 · empty on purpose · ACS after-treatment page names late or long-term treatment side effects after melanoma. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-melanoma-follow

Toxicity pointer

ACS-bcc-follow 2026 · empty on purpose · ACS after-treatment page names treatment side effects after basal cell carcinoma. Those late effects are not encoded. Keratinocyte carcinoma stays labeled separately. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-bcc-follow

Toxicity pointer

ACS-merkel-follow 2025 · empty on purpose · ACS living-as-a-survivor page names treatment side effects after Merkel cell carcinoma that might last a long time or show up years later. Those late effects are not encoded. Merkel cell carcinoma stays labeled separately. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-merkel-follow

Toxicity pointer

ACS-kaposi-follow 2025 · empty on purpose · ACS after-treatment page names treatment side effects after Kaposi sarcoma. Those late effects are not encoded. Kaposi sarcoma stays labeled separately. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-kaposi-follow

Toxicity pointer

ACS-melanoma-follow 2026 · empty on purpose · ACS after-treatment page names later cancers after melanoma treatment. Those second-cancer risks are not encoded. Complementary to the AAD melanoma flag. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-melanoma-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later cancer-related fatigue and a treatment summary for possible late effects. Those late effects are not encoded. Keratinocyte carcinoma stays labeled separately. Complementary to the AAD first row. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after skin treatment. Those named tests are not encoded. Keratinocyte carcinoma stays labeled separately. Complementary to the AAD first row. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — Skin

Acute: ACS names field dermatitis, fatigue, hair loss in the field, and tenderness. Late: darker or more sensitive skin, texture change, field-skin counseling after chest RT, another skin cancer in or near the field, and lasting fatigue. Monitor: field infection during RT; new or changing lesions; lasting fatigue or sleep problems; a treatment summary. Those names are not encoded. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

• Cancer-related fatigue that lasts
• Joint or muscle pain after some treatments
• Mental health and distress after treatment
• Treatment summary for later problems

Named conditions to monitor

• Field infection or severe dermatitis
• New or changing lesion after melanoma or keratinocyte RT
• Second-cancer testing after melanoma
• Ask for a treatment summary
• Cancer-related fatigue or sleep problems that last
• Joint or muscle pain after chemo, steroids, or hormone therapy
• Anxiety, depression, or fear of recurrence after treatment
• Second-cancer awareness after radiation or chemo
• Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS field-skin and melanoma / BCC names only. Complementary ACS long-term page is named, not encoded. Keratinocyte stays labeled separately. No invented NCCN month table.

SEER 5-year relative survival by stage

Localized 99.6% · Regional 73.9% · Distant 35.1% · All 94.7%

Melanoma of the skin. Keratinocyte carcinomas are not SEER-reportable.

Percent of cases by stage (SEER Stat Facts)

Localized 77% · Regional 10% · Distant 5% · Unknown 9%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Melanoma of the skin.

Fitzpatrick 3 · no outdoor-work flag · USPSTF 2023: I statement — insufficient evidence for population visual screening

• screening

  USPSTF 2023 I — phenotype counseling, not a population interval

  Fitzpatrick 3

  empty on purpose

• surveillance

  After melanoma — specialist calendar

  No melanoma on this fixture — no surveillance calendar

  empty on purpose

• toxicity

  In-field skin after chest RT is a Hodgkin late-effect, not melanoma incidence

  In-field skin awareness after chest RT

  on this plan

Fitzpatrick 1 · outdoor work · USPSTF 2023: I statement — insufficient evidence for population visual screening

• screening

  USPSTF 2023 I — phenotype counseling, not a population interval

  Phenotype counseling after melanoma — not a population visual-screen interval

  on this plan

• surveillance

  After melanoma — specialist calendar

  Specialist melanoma follow-up — no invented NCCN month table

  on this plan

• toxicity

  In-field skin after chest RT is a Hodgkin late-effect, not melanoma incidence

  Empty on purpose — no chest-RT skin flag

  empty on purpose

Fitzpatrick 3 · no outdoor-work flag · USPSTF 2023: I statement — insufficient evidence for population visual screening

• screening

  USPSTF 2023 I — phenotype counseling, not a population interval

  Fitzpatrick 3

  empty on purpose

• surveillance

  After melanoma — specialist calendar

  No melanoma on this fixture — no surveillance calendar

  empty on purpose

• toxicity

  In-field skin after chest RT is a Hodgkin late-effect, not melanoma incidence

  Empty on purpose — no chest-RT skin flag

  empty on purpose

Fitzpatrick 4 · no outdoor-work flag · USPSTF 2023: I statement — insufficient evidence for population visual screening

• screening

  USPSTF 2023 I — phenotype counseling, not a population interval

  Fitzpatrick 4

  empty on purpose

• surveillance

  After melanoma — specialist calendar

  No melanoma on this fixture — no surveillance calendar

  empty on purpose

• toxicity

  In-field skin after chest RT is a Hodgkin late-effect, not melanoma incidence

  Empty on purpose — no chest-RT skin flag

  empty on purpose